Cargando…

Isocitrate dehydrogenase mutations: new opportunities for translational research

Over the last decade, comprehensive genome-wide sequencing studies have enabled us to find out unexpected genetic alterations of metabolism in cancer. An example is the identification of arginine missense mutations of isocitrate dehydrogenases-1 and -2 (IDH1/2) in glioma, acute myeloid leukemia (AML...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keum, Young-Sam, Choi, Bu Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Biochemistry and Molecular Biology 2015
Materias:	Contributed Mini Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578565/ https://www.ncbi.nlm.nih.gov/pubmed/25787993 http://dx.doi.org/10.5483/BMBRep.2015.48.5.021

Ejemplares similares

Identification of a New Selective Chemical Inhibitor of Mutant Isocitrate Dehydrogenase-1
por: Kim, Hyo-Joon, et al.
Publicado: (2015)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
por: Hvinden, Ingvild Comfort, et al.
Publicado: (2021)

Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma
por: Lu, Victor M, et al.
Publicado: (2018)

Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
por: Testa, Ugo, et al.
Publicado: (2020)

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
por: Liu, Yang, et al.
Publicado: (2020)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Isocitrate dehydrogenase variants in cancer — Cellular consequences and therapeutic opportunities
por: Liu, Shuang, et al.
Publicado: (2020)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
por: Neumaier, Felix, et al.
Publicado: (2023)

Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials
por: Sharma, Nikhil, et al.
Publicado: (2023)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease
por: Tommasini-Ghelfi, Serena, et al.
Publicado: (2019)

Degradation of D-2-hydroxyglutarate in the presence of isocitrate dehydrogenase mutations
por: Berger, Raffaela S., et al.
Publicado: (2019)

Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas
por: Hsieh, Kevin Li-Chun, et al.
Publicado: (2017)

EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

Isocitrate Dehydrogenase 1 and 2 Mutations in Pediatric Neuroblastoma Patients
por: LEVENTOGLU, Emre, et al.
Publicado: (2023)

Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
por: Al-Khallaf, Hamoud
Publicado: (2017)

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
por: Liu, Yang, et al.
Publicado: (2023)

Radiological Surveillance Screening in Asymptomatic Succinate Dehydrogenase Mutation Carriers
por: Tufton, Nicola, et al.
Publicado: (2017)

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
por: Alzial, Gabriel, et al.
Publicado: (2021)

Isocitrate dehydrogenase gene variants in cancer and their clinical significance
por: Cadoux-Hudson, Thomas, et al.
Publicado: (2021)

Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma
por: Lai, Grace, et al.
Publicado: (2015)

Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone
por: Kato Kaneko, Mika, et al.
Publicado: (2014)

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
por: Huang, Juan, et al.
Publicado: (2019)

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
por: Gallus, Marco, et al.
Publicado: (2023)

The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells
por: Smolková, Katarína, et al.
Publicado: (2012)

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
por: OHBA, Shigeo, et al.
Publicado: (2016)

The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes
por: Ishida, Tomoaki, et al.
Publicado: (2021)

Consequences of oncogenic isocitrate dehydrogenase mutations and 2-hydroxyglutarate production in prostate epithelium
por: Over, Jon A, et al.
Publicado: (2013)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients
por: Auezova, Raushan, et al.
Publicado: (2019)

A novel isocitrate dehydrogenase 1 G131D mutation in glioblastoma
por: Wang, Lei-Ming, et al.
Publicado: (2021)

Chromatin-regulating genes are associated with postoperative prognosis and isocitrate dehydrogenase mutation in astrocytoma
por: Zhang, Kun, et al.
Publicado: (2020)

Hub gene identification and prognostic model construction for isocitrate dehydrogenase mutation in glioma
por: Jia, Yanfei, et al.
Publicado: (2020)

Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma
por: Lang, Fengchao, et al.
Publicado: (2021)

Identification of medicinal compounds as potential inhibitors for mutated isocitrate dehydrogenases against chondrosarcoma
por: Shah, Fahad Hassan, et al.
Publicado: (2022)

Advanced multiparametric MRI-based scoring for isocitrate dehydrogenase mutation prediction of gliomas
por: Hosur, Bharat, et al.
Publicado: (2022)

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities
por: Oh, Sejin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f04s6csic12brnj4pvn55859u7